METFORMIN AT TOLERATED HUMAN DOSE INHIBITS BREAST CANCER ALSO VIA ACTIVATING CYCLIC AMPK

 This column discussed a month ago the multiple benefits of metformin including halving new diabetes and deaths, and  reducing cancers- whereas induced hypocholesterolemia may increase cancer.

 

The thoughtful analytical letter from Toronto University’s Cancer Institute (Stambolic et al ) highlights the gulf between rodent experiments and human experience, between mice and (wo)men.

 

        While not decrying the theoretical risk of neoangiogenesis, they remind that in humans metformin reduces incidence of cancer when it  is used at modest daily doses to reduce hyperglycemia and insulin resistance;  not at the 300fold higher bloodlevels  used in rodents and with superabundant nutrients used to grow cancer cells in petri dishes.

        Similarly their McGill  associates Ryan et al in 2007  showed in vitro  that Metformin Inhibits Mammalian Target of Rapamycin–Dependent Translation Initiation in Breast Cancer Cells via AMPK.

 

 

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s